Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. J of Skin [Internet]. 2021 Jan. 1 [cited 2025 Apr. 19];5(1):s2. Available from: https://skin.dermsquared.com/skin/article/view/1154